NeuWave Medical’s ablation technology was developed at the University of Wisconson, Ethicon said. The company’s Certus 140 ablation system allows for single or simultaneous multiple probe procedures in patients with soft tissue lesions.
“Currently, there are limited treatment options for soft-tissue, non-resectable lesions. Together with NeuWave Medical, Ethicon can bring minimally invasive treatment options to make a difference for patients around the world. This is especially important for patients who may not be medically eligible for traditional surgery. We can now offer physicians and patients more choice in treatment options for soft-tissue lesions.,” Ethicon company group chair Michael del Prado said in a statement to the press.
NeuWave won FDA premarket approval for its Ablation Confirmation software last July, saying it would be integrated into its Intelligent Ablation system.
The computer-controlled ablation system also has greater access to data gained during the process and is able to use it to streamline the procedure, CEO Dan Sullivan told MassDevice.com in an interview.
“NeuWave Medical’s unique ablation technology was originally developed by physicians and microwave scientists from theUniversity of Wisconsin to maximize energy delivery to tissue, minimize invasiveness and provide physician-friendly workflow. This acquisition now provides NeuWave Medical with the ability to accelerate our innovation pipeline and expand the global footprint of our unique technologies, while allowing Ethicon to reach new patients by expanding the availability of a novel intervention that goes beyond surgical options in wide use today,” CEO Sullivan said.
The acquisition was 1st announced in March. Financial and other terms of the deal were not announced.